BACKGROUND: Procalcitonin (PCT) was widely investigated in febrile neutropenia as an indirect marker of infection. Many institutions also use PCT as a tool to monitor the course of a febrile episode because increases in PCT values during the febrile episode were associated with development of complications. However, to date, no study systematically evaluated the accuracy of decreasing PCT values in predicting favorable outcomes of a febrile episode. The aim of this study was to evaluate the changes in PCT values after resolution of fever with regard to their predictive value of stable defervescence. MATERIALS AND METHODS: PCT was studied prospectively in 94 febrile episodes of 35 patients with hematological malignancies. RESULTS: Sixty-seven episodes were associated with an increased level of PCT at the beginning. In these episodes, stable resolution of fever was significantly correlated with a decrease in PCT values. The best cut-off level to predict freedom from recurrence of fever for at least 5 days was <70% of the maximum PCT value on the second afebrile day. Out of 44 patient episodes with a subsequent decrease to <70%, only two patients had recurrent fever within the next 5 days, revealing a negative predictive value of 95%, p<0.001. CONCLUSION: Our study supports the value of PCT as a reliable tool to predict clinical outcome in febrile neutropenia.
BACKGROUND: Procalcitonin (PCT) was widely investigated in febrile neutropenia as an indirect marker of infection. Many institutions also use PCT as a tool to monitor the course of a febrile episode because increases in PCT values during the febrile episode were associated with development of complications. However, to date, no study systematically evaluated the accuracy of decreasing PCT values in predicting favorable outcomes of a febrile episode. The aim of this study was to evaluate the changes in PCT values after resolution of fever with regard to their predictive value of stable defervescence. MATERIALS AND METHODS: PCT was studied prospectively in 94 febrile episodes of 35 patients with hematological malignancies. RESULTS: Sixty-seven episodes were associated with an increased level of PCT at the beginning. In these episodes, stable resolution of fever was significantly correlated with a decrease in PCT values. The best cut-off level to predict freedom from recurrence of fever for at least 5 days was <70% of the maximum PCT value on the second afebrile day. Out of 44 patient episodes with a subsequent decrease to <70%, only two patients had recurrent fever within the next 5 days, revealing a negative predictive value of 95%, p<0.001. CONCLUSION: Our study supports the value of PCT as a reliable tool to predict clinical outcome in febrile neutropenia.
Authors: Walter T Hughes; Donald Armstrong; Gerald P Bodey; Eric J Bow; Arthur E Brown; Thierry Calandra; Ronald Feld; Philip A Pizzo; Kenneth V I Rolston; Jerry L Shenep; Lowell S Young Journal: Clin Infect Dis Date: 2002-02-13 Impact factor: 9.079
Authors: Chris Barnes; Vera Ignjatovic; Fiona Newall; John Carlin; Felicia Ng; Simone Hamilton; David Ashley; Keith Waters; Paul Monagle Journal: Br J Haematol Date: 2002-09 Impact factor: 6.998
Authors: Mirjam Christ-Crain; Daiana Jaccard-Stolz; Roland Bingisser; Mikael M Gencay; Peter R Huber; Michael Tamm; Beat Müller Journal: Lancet Date: 2004-02-21 Impact factor: 79.321
Authors: Lothar Hambach; Matthias Eder; Elke Dammann; Andreas Schrauder; Karl-Walter Sykora; Christian Dieterich; Philip Kirschner; Jürgen Novotny; Arnold Ganser; Bernd Hertenstein Journal: Haematologica Date: 2002-06 Impact factor: 9.941
Authors: H Giamarellou; E J Giamarellos-Bourboulis; P Repoussis; L Galani; N Anagnostopoulos; P Grecka; D Lubos; M Aoun; K Athanassiou; E Bouza; E Devigili; V Krçmery; F Menichetti; E Panaretou; E Papageorgiou; D Plachouras Journal: Clin Microbiol Infect Date: 2004-07 Impact factor: 8.067
Authors: Shin Ahn; Yoon-Seon Lee; Yun-Hee Chun; In-Ho Kwon; Won Kim; Kyung Soo Lim; Tae Won Kim; Kyoo-Hyung Lee Journal: Support Care Cancer Date: 2010-06-16 Impact factor: 3.603
Authors: Paul R J Ames; Emily Walker; Darren Aw; David Marshall; Francois de Villiers; Manfred Staber Journal: Clin Rheumatol Date: 2008-10-07 Impact factor: 2.980